Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Perturbagen Concentration | Perturbagen Conc Unit | Biological Replicate ID | Relative Cell Count | Normalized Growth Rate Inhibition Value | Nominal Division Rate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AU565 | HER2amp | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 0.904 | uM | 5900.092 | 1.0290 | 1.0218 | 2.6334 | |
| AU565 | HER2amp | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 4.52 | uM | 5900.092 | 0.9614 | 0.9704 | 2.6334 | |
| AU565 | HER2amp | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 22.6 | uM | 5900.092 | 0.5536 | 0.5977 | 2.6334 | |
| AU565 | HER2amp | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 113 | uM | 5900.092 | 0.0079 | -0.6812 | 2.6334 | |
| AU565 | HER2amp | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 565 | uM | 5900.092 | 0.0041 | -0.7508 | 2.6334 | |
| AU565 | HER2amp | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 0.00145 | uM | 5901.091 | 0.9294 | 0.9252 | 1.9229 | |
| AU565 | HER2amp | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 0.00723 | uM | 5901.091 | 1.0120 | 1.0125 | 1.9229 | |
| AU565 | HER2amp | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 0.0362 | uM | 5901.091 | 0.9971 | 0.9970 | 1.9229 | |
| AU565 | HER2amp | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 0.181 | uM | 5901.091 | 0.9740 | 0.9728 | 1.9229 | |
| AU565 | HER2amp | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 0.904 | uM | 5901.091 | 0.9875 | 0.9869 | 1.9229 | |
| AU565 | HER2amp | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 4.52 | uM | 5901.091 | 0.9529 | 0.9505 | 1.9229 | |
| AU565 | HER2amp | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 22.6 | uM | 5901.091 | 0.4552 | 0.3282 | 1.9229 | |
| AU565 | HER2amp | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 113 | uM | 5901.091 | 0.0077 | -0.8406 | 1.9229 | |
| AU565 | HER2amp | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 565 | uM | 5901.091 | 0.0049 | -0.8741 | 1.9229 | |
| BT-20 | TNBC | Basal A | Imatinib | ABL/KIT/PDGFR | nRTK | 0.00145 | uM | 5902.091 | 0.9666 | 0.9425 | 1.1648 | |
| BT-20 | TNBC | Basal A | Imatinib | ABL/KIT/PDGFR | nRTK | 0.00723 | uM | 5902.091 | 1.0240 | 1.0411 | 1.1648 | |
| BT-20 | TNBC | Basal A | Imatinib | ABL/KIT/PDGFR | nRTK | 0.0362 | uM | 5902.091 | 1.0028 | 1.0048 | 1.1648 | |
| BT-20 | TNBC | Basal A | Imatinib | ABL/KIT/PDGFR | nRTK | 0.181 | uM | 5902.091 | 0.9905 | 0.9837 | 1.1648 | |
| BT-20 | TNBC | Basal A | Imatinib | ABL/KIT/PDGFR | nRTK | 0.904 | uM | 5902.091 | 1.0084 | 1.0144 | 1.1648 | |
| BT-20 | TNBC | Basal A | Imatinib | ABL/KIT/PDGFR | nRTK | 4.52 | uM | 5902.091 | 0.9393 | 0.8953 | 1.1648 | |
| BT-20 | TNBC | Basal A | Imatinib | ABL/KIT/PDGFR | nRTK | 22.6 | uM | 5902.091 | 0.7797 | 0.6152 | 1.1648 | |
| BT-20 | TNBC | Basal A | Imatinib | ABL/KIT/PDGFR | nRTK | 113 | uM | 5902.091 | 0.0211 | -0.9272 | 1.1648 | |
| BT-20 | TNBC | Basal A | Imatinib | ABL/KIT/PDGFR | nRTK | 565 | uM | 5902.091 | 0.0075 | -0.9699 | 1.1648 | |
| BT-20 | TNBC | Basal A | Imatinib | ABL/KIT/PDGFR | nRTK | 0.00145 | uM | 5903.09 | 0.9297 | 0.8490 | 0.9291 | |
| BT-20 | TNBC | Basal A | Imatinib | ABL/KIT/PDGFR | nRTK | 0.00723 | uM | 5903.09 | 1.0085 | 1.0184 | 0.9291 |